BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37984629)

  • 1. Amphiphilic polymeric nanodrug integrated with superparamagnetic iron oxide nanoparticles for synergistic antibacterial and antitumor therapy of colorectal cancer.
    Li X; Niu J; Deng L; Yu Y; Zhang L; Chen Q; Zhao J; Wang B; Gao H
    Acta Biomater; 2024 Jan; 173():432-441. PubMed ID: 37984629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against
    Su M; Wen X; Yu Y; Li N; Li X; Qu X; Elsabahy M; Gao H
    J Mater Chem B; 2024 Apr; 12(16):3947-3958. PubMed ID: 38586917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusobacterium nucleatum-triggered neutrophil extracellular traps facilitate colorectal carcinoma progression.
    Kong X; Zhang Y; Xiang L; You Y; Duan Y; Zhao Y; Li S; Wu R; Zhang J; Zhou L; Duan L
    J Exp Clin Cancer Res; 2023 Sep; 42(1):236. PubMed ID: 37684625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression.
    Jia F; Yu Q; Wang R; Zhao L; Yuan F; Guo H; Shen Y; He F
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Targeting Nanoassembly for Enhanced Colorectal Cancer Therapy by Eliminating Intratumoral
    Li X; Ma Y; Xin Y; Ma F; Gao H
    ACS Appl Mater Interfaces; 2023 Mar; ():. PubMed ID: 36916659
    [No Abstract]   [Full Text] [Related]  

  • 6. Remotely Controllable Supramolecular Nanomedicine for Drug-Resistant Colorectal Cancer Therapy Caused by Fusobacterium nucleatum.
    Yan X; Xin Y; Yu Y; Li X; Li B; Elsabahy M; Zhang J; Ma F; Gao H
    Small Methods; 2024 Mar; 8(3):e2301309. PubMed ID: 38018349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
    Zhang S; Yang Y; Weng W; Guo B; Cai G; Ma Y; Cai S
    J Exp Clin Cancer Res; 2019 Jan; 38(1):14. PubMed ID: 30630498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin/β-catenin/GPX4 axis in colorectal cancer.
    Li B; Wei Z; Wang Z; Xu F; Yang J; Lin B; Chen Y; Wenren H; Wu L; Guo X; Liu Y; Wei Y
    Free Radic Biol Med; 2024 Aug; 220():125-138. PubMed ID: 38657754
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Hu L; Liu Y; Kong X; Wu R; Peng Q; Zhang Y; Zhou L; Duan L
    Front Immunol; 2021; 12():658681. PubMed ID: 34093546
    [No Abstract]   [Full Text] [Related]  

  • 10. [Advances on the treatment of
    Wang H; Hou X; Liu J; Yang C
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3670-3680. PubMed ID: 37805845
    [No Abstract]   [Full Text] [Related]  

  • 11. A homologous membrane-camouflaged self-assembled nanodrug for synergistic antitumor therapy.
    Xie X; Li Z; Tang H; Zhang Y; Huang Y; Zhang F; You Y; Xu L; Wu C; Yao Z; Peng X; Zhang Q; Li B
    Acta Biomater; 2024 Jun; ():. PubMed ID: 38838903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomes secreted by Fusobacterium nucleatum-infected colon cancer cells transmit resistance to oxaliplatin and 5-FU by delivering hsa_circ_0004085.
    Hui B; Zhou C; Xu Y; Wang R; Dong Y; Zhou Y; Ding J; Zhang X; Xu J; Gu Y
    J Nanobiotechnology; 2024 Feb; 22(1):62. PubMed ID: 38360615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism.
    Chen T; Li Q; Wu J; Wu Y; Peng W; Li H; Wang J; Tang X; Peng Y; Fu X
    Cancer Immunol Immunother; 2018 Oct; 67(10):1635-1646. PubMed ID: 30121899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    LaCourse KD; Zepeda-Rivera M; Kempchinsky AG; Baryiames A; Minot SS; Johnston CD; Bullman S
    Cell Rep; 2022 Nov; 41(7):111625. PubMed ID: 36384132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism.
    Ou S; Wang H; Tao Y; Luo K; Ye J; Ran S; Guan Z; Wang Y; Hu H; Huang R
    Front Cell Infect Microbiol; 2022; 12():1020583. PubMed ID: 36523635
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kim HS; Kim CG; Kim WK; Kim KA; Yoo J; Min BS; Paik S; Shin SJ; Lee H; Lee K; Kim H; Shin EC; Kim TM; Ahn JB
    Front Cell Infect Microbiol; 2023; 13():1101291. PubMed ID: 36960042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Intratumoral
    Qu X; Yin F; Pei M; Chen Q; Zhang Y; Lu S; Zhang X; Liu Z; Li X; Chen H; Zhang Y; Qin H
    ACS Nano; 2023 Jun; 17(12):11466-11480. PubMed ID: 37201179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSH-responsive degradable nanodrug for glucose metabolism intervention and induction of ferroptosis to enhance magnetothermal anti-tumor therapy.
    Liao Z; Wen E; Feng Y
    J Nanobiotechnology; 2024 Apr; 22(1):147. PubMed ID: 38570829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium New Houttuyfonate Inhibits Cancer-Promoting
    Jia F; Yu Q; Zhao L; Shen Y; Guo H; He F
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ-activated photothermal nanoplatform for on-demand NO gas delivery and enhanced colorectal cancer treatment.
    Xin Y; Yu Y; Su M; Li X; Elsabahy M; Gao H
    J Control Release; 2023 Jul; 359():69-84. PubMed ID: 37245723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.